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Introduction: Biobanks may play a pivotal role in lung cancer
patients’ management, research, and health policy. The Nancy
“Centre of Biologic Resources” analyzed the evolving profiles of
operated lung cancer patients and their management over 20 years.
Methods: A total of 1259 consecutive patients operated upon from
1988 till 2007 were included. Survival rates were statistically com-
pared before and after 1997. The parameters associated with a
significant improvement of survival were determined.
Results: After 1997, lung cancer was diagnosed at an earlier stage.
For Squamous Cell Lung Cancer (SQCLC), stages IA increased
from 5.4 to 19.5% and for Adenocarcinoma (ADC), stage IA
increased from 9.9 to 24.7%. More women with stage I ADC were
operated upon after 1997 (p  0.01). More patients with Large Cell
Lung Cancer were diagnosed recently. Recent patients received
more adjuvant or neo-adjuvant chemotherapy (p  0.001) and less
radiotherapy (stage I SQCLC: p  0.019, stage I ADC: p  0.001).
A longer overall patients’ survival was observed after 1997 (2 test
for SQLC and ADC independently p 0.002). Among SQCLC long
survivors, those at stage I-II, below 50 years, were more numerous.
A longer survival was associated with early stage in ADC patients.
Stage was the single constant factor for overall outcome.
Conclusion: Overall and stage-adjusted survival of operated lung
cancer patients has been improved in the last decade due mainly to
earlier diagnosis. The generalized use of computed tomography
scan, chemotherapy, and a collegial management improved patients’
survival.
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Lung cancer is one of the world’s leading causes of cancerrelated death.1 Europe and North America have the highest
incidence rates.2 At the beginning of the 21st century, there were
about 375,000 cases of lung cancer in Europe resulting in about
347,000 deaths.2 This incidence raised in 2004 to 381,500 cases.
In France, about 28,000 new cases are recorded annually.3 It is
the first cause of cancer-related death in men and the fourth in
women.4 The region of Lorraine is severely affected, having the
second highest incidence in France.4
Surgical resection is the treatment of choice for both
nonadvanced and selected advanced patients.5 Though the
French “Institut National de la Sante´ et de la Recherche
Me´dicale” created Center of Biological Resources (CRB)s for
research purposes, they are shown here to be of greater value.
Nancy CRB has been developed in the Nancy Central Hos-
pital, aiming to recruit operated lung cancer patients willing
to donate their samples for cancer research.6 The CRB has
accrued 1259 patients retrospectively from 1988.
In 1997, although the World Health Organization
(WHO) lung cancer staging was modified, lung cancer man-
agement became collegial in Nancy Central Hospital. After
1997, the postoperative follow-up included a new 3 months
out-patient evaluation by both a surgeon and a chest physi-
cian to decide on further management.
The goal of the study was to evaluate the evolving
clinical presentation of the operable lung cancer disease and
its management during the last 19 years in a single institution.
Moreover, survival was analyzed with respect to parameters
for surgery modality and additional treatment indications
adjusting for the initial cancer stage. The characteristics of
long survivors were assessed.
PATIENTS AND METHODS
Patients
The CRB collection was initiated in 1988 to store
tissues samples of patients operated for lung tumors as a
resource for research purposes. From 2002, all survivors and
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new patients were invited to give their informed consent,
offer access to their medical records, retrieve their pre and
postoperative management, and to donate biologic material
for research. Standard operating procedures were followed
for all steps of samples collection and storage and for the
retrieval of clinical annotations culminating in ISO 9001
certification of the biobank.
A retrospective study in which 1259 consecutive pa-
tients operated upon for primary lung cancer were followed
up from 1988 to 2007 was conducted by the CRB. The
information regarding demographic variables, such as age,
gender, and smoking habits was collected. Familial and
personal cancer histories with eventual occurrence of previ-
ous cancers and apparition of second primaries were re-
corded. The type of surgical resection and all relevant follow-
up, preop and/or postoperative treatments, and the date and
cause of death were registered. Tumor related data included
tumor histotyping and tumor, node, metastasis (pTNM) stag-
ing (WHO version 6) and tumor size.
Postoperative mortality was considered as death occur-
rence upto 45 days after surgery. Second lung primary was
considered when occurring at least 2 months after the first
lung cancer surgery.
Study period was divided in two semi-periods, using
1997 as a cutoff year. In 1997, three important changes were
enrolled concerning the management of operable lung cancer
patients: the revision of TNM system, the generalization of
computed tomography (CT) scan use in our area and the
adoption of a collegial decision procedure.
The initial follow-up included a contact of the surgeon
1 month after the operation and every 6 months thereafter for
2 years. Then, general practitioners or chest physicians took
care of the patients with varying schedules. In 1997, a first
collegial examination was added of each patient candidate to
surgery: the collegial management team included an oncolo-
gist, a surgeon, a chest physician, and a radiologist. Thus,
adjuvant chemotherapy became a usual practice for certain
patients. A supplementary contact was added 3 months after
the operation with the surgeon and the chest physician.
Follow-up by chest physicians was extended upto 7 years. CT
scan use was generalized in our area by early 1997. No
patient was lost to follow-up.
Statistical Analysis
The primary goal of this study was to compare survival
in the two periods and analyze parameters correlated with
survival. We also aimed to determine for each histologic type
the predictive significance of each clinical parameter on the
overall survival. All statistical analyses were done on the full
patient subset and were carried out with the Stata software
(StataCorp, College Station, Texas). Patient survival was
described by a standard Kaplan- Meier estimate stratified on
disease staging. If the patient died during the follow-up,
patient survival was censured at the time of death. Long
survivors were defined as free from clinical and radiologic
local or distant relapse 5 years after surgery. The predictive
significance of each parameters was then tested univariatly in
a nonparametric fashion by generalized Wilcoxon rank tests
conducted at the 5% significance (level alpha 0.05). To
model the survival with multiple parameters, we used a Cox
proportional hazard model stratified on tumor. Stage was
used to assess the simultaneous contribution of the different
covariates. The following variables were considered for
entering the model: age, sex, tumor staging, smoking
history, extent of surgery, preop and postoperative treat-
ments. The Cox models were developed in a forward
fashion based on changes in log-likelihood. Interactions
between survival and the different parameters were also
considered. Possible confounding effects by the other
factors were systematically assessed. The results of the
Cox model are given as hazard ratios by which the hazard
of relapse is multiplied when the factor is present versus
when it is absent. Postoperative mortality was analyzed
using unconditional logistic regression and the results
were expressed as odds ratios (OR).
RESULTS
Description of the Cohort
The epidemiological characteristics of our cohort are
presented in Table 1. The population was mainly males
(86.33%) and smokers (94.12%). The two most represented
histologic types were squamous cell lung cancer (SQCLC)
(49.64%) and adenocarcinoma (ADC) (38.68%). The 40.27%
of the cohort was included in the period before 1997, whereas
those included after 1997 represent 59.73%. Patients with
stage IV lung cancer were a minority (4.92%). This is not
peculiar because stage IV is inoperable by definition. Under
special circumstances (young age, one isolated metastasis
etc), some patients with stage IV lung cancer may be operated
TABLE 1. Main Characteristics of the Cohort in Number
and Percentage of Patients
Age (mean  SD) in years 61.62  9.72
Males 1.087 (86.33%)
Females 172 (13.67%)
Smokers 1.185 (94.12%)
Never smokers 74 (5.88%)
Smoking history (pack/yrs) 41.26  22.1
SQCLC 625 (49.64%)
ADC 487 (38.68%)
LCLC 74 (5.88%)
NELT 73 (5.80%)
Stages
IA 193 (15.32%)
IB 361 (28.67%)
IIA 44 (3.49%)
IIB 238 (18.9%)
IIIA 228 (18.10%)
IIIB 133 (10.56%)
IV 62 (4.92%)
Period 1: 1988–1997 507 (40.27%)
Period 2: 1997–2007 753 (59.73%)
Total 1.259
SQCLC, squamous cell lung cancer; ADC, adenocarcinoma; LCLC, large cell lung
cancer; NELT, neuroendocrine lung tumors.
Vlastos et al. Journal of Thoracic Oncology • Volume 4, Number 4, April 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer506
upon but their number is usually small. Patients with stage
IIA disease were 3.49%, indicating the relative rarity of this
stage. The description of the histologic subgroups with their
demographic, clinical and surgical characteristics is summa-
rized in Table 2.
SQCLC patients tented to be older, although large cell
lung cancer (LCLC) or ADC patients tended to smoke less.
Mean smoking cessation period was longer for patients with
SQCLC.
Survival—Comparison Between the Two
Periods
The lung cancer related mortality of the cohort was
43.48% (527 of 1259 patients). Overall survival has been
statistically increased for patients with SQCLC (2  13.73,
p 0.002) or ADC (2  18.04, p 0.001) during the recent
period. The number of operated lung cancer patients who
died of their disease decreased during the recent period (245
versus 282). The proportion of patients who died in the
previous and recent period was respectively 55.62 and
32.57%. Table 3 shows that the proportion of stage IA
diagnosis increased sharply after 1997 for both main histo-
types. The comparison of the estimated mortality rates be-
tween the two periods in these histotypes is shown in Table
4. Mortality rate ratios of the recent period comparing with
the previous period for patients with SQCLC were signifi-
cantly decreased for stages IB (0.057 versus 0.098) and IIB
(0.086 versus 0.171). For patients with ADC, the respective
significant rate ratios concerned the stages IB: (0.063 versus
0.110) and IIIA: (0.217 versus 0.496).
The number of pneumonectomies decreased during the
recent years in favor of more limited resections (Tables 2).
Overall postoperative mortality was 4.1 and 8.3%, for ADC
and SQCLC respectively. It remained statistically unaffected
along the two studied periods.
The diagnosis of earlier SQCLC or ADC was more
frequent after 1997. In patients with SQCLC, stages IA and
IB increased from 5.41 to 19.57% and from 30.50 to 32.44%,
respectively. In ADC, stage IA levelled from 9.90 to 24.75%.
More ex-smokers with SQCLC stage I and more women with
ADC stage I were operated after 1997 (p  0.01 and p 
0.02, respectively).
Incidence of stage III presented a different evolution:
SQCLC patients with IIIA disease were fewer recently (14.7
versus 23.9%), although stage IIIA ADC patients were almost
equal between the two periods. Fewer patients with stage IV
disease were operated in both histologic subgroups during the recent
period.
Additional treatments were associated with opposite
outcome regarding stage-adjusted survival. In stage I SQCLC
patients, preoperative chemotherapy was more frequent after
1997 (p  0.04), although postoperative radiotherapy was
rarer (p  0.01) (Table 4). In stage I ADC, postoperative
chemotherapy increased steadily after 1997 (p  0.001),
although postoperative radiotherapy dropped (p  0.001). In
stage III SQCLC patients, postoperative chemotherapy in-
creased after 1997 (p  0.001), although postoperative ra-
diotherapy diminished (p  0.02) (Table 4). In stage III ADC
patients, postoperative chemotherapy increased after 1997
(p  0.001) and postoperative radiotherapy diminished (p 
0.001). This may contribute to the differences in stage-
adjusted survival between the two periods. SQCLC patients
with stages IB and IIB and ADC patients with stages IB and
IIIA survived longer during the recent period. The effect of
TABLE 2. Demographic, Clinical, and Surgical Characteristics of the Histological Subgroups, in Numbers of Patients and in
Percentage
SQCLC ADC LCLC NELT Total
Males 573 (91.6%) 396 (81.3%) 57 (77.0%) 61 (83.5%) 1087
Females 52 (8.4%) 91 (18.7%) 17 (23.0%) 12 (16.5%) 172
Age in years (SD) 63.19 (9.5) 60.15 (9.68) 58.10 (10.45) 61.34 (8.9)
Never smokers 10 (1.6%) 54 (11.1%) 4 (5.4%) 6 (8.2%) 84
Smokers 615 (98.4%) 433 (88.9%) 70 (94.6%) 67 (91.8%) 1175
Smoking habits pack/years (SD) 43.64 (20.0) 38.55 (23.5) 37.02 (18.9) 43.43(29.2)
(pTNM) stage
IA 87 (13.9%) 92 (18.9%) 5 (6.8%) 8 (10.8%) 192
IB 196 (31.3%) 138 (28.3%) 19 (25.6%) 11 (15.0%) 364
IIA 28 (4.5%) 12 (2.5%) 3 (4.0%) 4 (5.7%) 47
IIB 118 (18.9%) 87 (17.9%) 16 (21.6%) 13 (17.7%) 234
IIIA 116 (18.6%) 79 (16.2%) 19 (25.6%) 14 (19.1%) 228
IIIB 64 (10.2%) 45 (9.2%) 7 (9.6%) 19 (26.0%) 135
IV 16 (2.6%) 34 (7.0%) 5 (6.8%) 4 (5.7%) 59
Period 1 257 (41.1%) 192 (39.4%) 14 (19.9%) 42 (57.5%) 507
Period 2 368 (58.9%) 295 (60.6%) 59 (80.1%) 30 (42.5%) 752
Pneumonectomies 225 (36.0%) 100 (20.5%) 46 (62.1%) 50 (68.4%) 421
Postoperative mortality 52 (8.3%) 20 (4.1%) 4 (5.4%) 6 (8.2%) 82
Overall mortality 235/625 220/487 33/74 39/73 527/1259
Overall mortality is also indicated for each group.
SQCLC, squamous cell lung cancer; ADC, adenocarcinoma; LCLC, large cell lung cancer; NELT, neuroendocrine lung tumors.
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chemotherapy upon the survival of stage III SQCLC patients
was not demonstrated. This is also true for stage IIB or IIIB
ADC patients.
An increase in the number of patients with LCLC was
observed during the recent period affecting more the females
(Table 2). More Neuroendocrine Lung Tumors were operated
after 1997 (44 versus 29).
Prognosis Factors for Survival
Prognosis factors for survival differed between the
major histologic types. Table 3 shows their respective hazard
ratios for the Cox regression analysis.
Stage was the single common prognosis factor for all
the patients (Figures 1, 2). In SQCLC patients, early stage
was an independent favorable predictor. A favorable trend
was observed for younger age and recent period. No signif-
icant association was found for sex or tobacco consumption
excepting for the increase of ex-smokers after 1997. In ADC
patients, early stage and the recent period were independent
positive predictors with favorable trends for never smoker
and female gender.
Tumor size did not affect SQCLC patients’ survival. A
T 4 cm (longest axis) was weakly associated with a short-
ened survival in ADC patients (log-rank test for equality of
survivor functions, p  0.311).
Pneumonectomy seemed as the major common deter-
minant of postoperative mortality in both groups (for patients
with SQCLC, the age-adjusted OR was 3.18 95% CI: 1.75–
5.81, whereas for patients with ADC was 3.29 95% CI:
1.31–8.25). SQCLC patients aged over 75 years were asso-
ciated with a higher postoperative mortality. In ADC, the
corresponding age-specific ORs versus age 55 years were
as follows; for the group of the 65 to 75 years old patients:
4.84 (95% CI 1.00–23.5), for those over 75 years: 2.68 (95%
CI: 0.23–30.9). Neither gender nor smoking status was sig-
nificant factors for postoperative mortality.
Long survivors had different profiles depending upon
the histology. SQCLC patients (42.90% of the patients still
alive) tented to be younger at the time of surgery (age 50
years) and had an earlier staged disease. For operated SQCLC
patients younger than 50 years, the OR of patients aged 50 to
60 years was 2.13, for patients aged 60 to 70 years was 2.99,
TABLE 3. Comparison Between the Two Periods for Operated Patients with SQCLC or ADC
Stage Period Number of Deaths Mortality Rate 95% Confidence Interval Ratio Rate 95% Confidence Interval
SQCLC
IA 2 6 0.084 0.038–0.188 3.11 1.00–9.64
1 6 0.030 0.012–0.060
IBa 2 32 0.057 0.039–0.083 0.59 0.35–0.97
1 28 0.098 0.069–0.139
IIA 2 5 0.092 0.029–0.287 0.92 0.22–3.83
1 3 0.101 0.042–0.243
IIBa 2 22 0.086 0.057–0.132 0.51 0.29–0.90
1 26 0.171 0.116–0.251
IIIA 2 37 0.240 0.174–0.332 1.40 0.80–2.43
1 19 0.172 0.109–0.269
IIIB 2 27 0.291 0.200–0.425 0.61 0.32–1.16
1 14 0.478 0.283–0.808
IV 2 7 1.254 0.598–2.632 7.47 1.93–28.89
1 3 0.167 0.054–0.520
ADC
IA 2 7 0.040 0.019–0.083 1.12 0.39–3.19
1 7 0.044 0.021–0.093
IBa 2 13 0.063 0.036–0.108 1.73 0.92–3.28
1 35 0.110 0.078–0.152
IIA 2 4 0.420 0.157–1.118 0.70 0.18–2.80
1 4 0.294 0.110–0.784
IIB 2 18 0.180 0.113–0.285 1.31 0.73–2.32
1 33 0.234 0.167–0.330
IIIAa 2 23 0.217 0.144–0.328 2.28 1.29–4.02
1 25 0.497 0.335–0.735
IIIB 2 17 0.432 0.268–0.695 0.96 0.46–1.97
1 13 0.413 0.240–0.712
IV 2 9 0.360 0.187–0.690 1.06 0.45–2.51
1 12 0.380 0.215–0.669
Estimated mortality rates with lower/upper bounds of 95% confidence intervals are presented.
aIndicate stages with statistically longer survival after 1997.
SQCLC, squamous cell lung cancer; ADC, adenocarcinoma.
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and for patients older than 70 years was 2.48. Furthermore,
advanced stages showed increased ORs compared with stage
IA. After stage adjustment, tobacco consumption was exam-
ined. Among SQCLC, the majority of long survivors were
recent quitters. Long survivors were fewer among the ADC
patients (33.88%). Although age at surgery was not a signif-
icant predictor for a longer survival, early stage, female sex,
and never smokers seemed to be independent positive pre-
dictors of a longer survival.
Second Primary, Recurrence of First Primary,
Personal and Familial History of Cancer
A nonnegligible group of both SQCLC and ADC pa-
tients presented a second primary lung cancer (6.01% for
SQCLC and 18 3.69% for ADC). This occurred in an interval
of 3.84 years (3.55) in SQCLC patients and of 3.84 years
(2.9) in ADC patients. Patients who presented a second
primary tented to be heavier smokers. Patients with initial
SQCLC tended to present a second primary of the same
histology, whereas patients with initial ADC presented as
much a second ADC than a second SQCLC.
Local recurrences of lung cancer needing a comple-
mentary surgery were observed in 12 patients with SQCLC
and 15 patients with ADC. The mean interval for such
recurrences was 1.5 (1.4) years for SQCLC patients and
1.5 (0.8) years for ADC patients. Stage-adjusted esti-
mated rates of mortality tented to be higher for such
patients.
TABLE 4. Comparison of Clinical and Pathological Characteristics of Operated Patients with Earlier or Advanced Stages
SQCLC or ADC Between the Periods 1988–1997 (Period 1) and 1997–2007 (Period 2)
Earlier Stages (I or II)
SQCLC (%) ADC (%)
Clinical and Pathological Characteristics Period 1 Period 2 Period 1 Period 2
Postoperative mortality 7 6.98 (p  0.99) 5.34 3.52 (p  0.42)
Age class in years
0–50 11.00 8.84 10.69 10.61
50–60 26.00 22.33 27.48 35.35
60–70 39.00 35.35 41.22 33.33
70 24.00 33.49 (p  0.39) 20.61 20.71 (p  0.41)
Mean age (SD) at surgery (in years) 64.71  9.62 62.68  9.53 61.26  9.51 62.25  9.46
Females 8.08 9.95 10.69 21.72
Males 91.92 90.05 (p  0.59) 89.31 78.28 (p  0.01)a
Ex-smokers 41.00 57.21 50.38 43.94
Smokers 57.00 41.86 40.46 45.96
Nonsmokers 2.00 0.93 (p  0.02)a 9.16 10.10 (p  0.5)
Preoperative radiotherapy 1.00 1.4 (p  0.77) 2.29 0.51 (p  0.14)
Postoperative radiotherapy 14.00 6.05 (p  0.01)a 29.77 5.05 (p  0.001)a
Preoperative chemotherapy 3.00 9.30 (p  0.04)a 0.76 7.07 (p  0.007)a
Postoperative chemotherapy 5.00 7.44 (p  0.41) 3.05 15.66 (p  0.001)a
Advanced stage (III)
Postoperative mortality 9.57 10.74 (p  0.7) 6.38 1.30 (p  0.12)
Age classes in years
0–50 11.30 9.09 14.89 20.78
50–60 23.48 26.45 42.55 35.06
60–70 45.22 33.88 34.04 24.68
70 20 30.58 (p  0.17) 8.51 19.48 (p  0.24)
Mean age (SD) at surgery (in years) 63.40  9.84 62.14  9.76 59.25  10.1 59.60  8
Females 3.51 9.17 14.89 23.38
Males 96.49 90.83 (p  0.07) 85.11 76.62 (p  0.25)
Ex-smokers 45.22 55.37 38.30 38.96
Smokers 52.17 42.98 48.94 48.05
Never smokers 2.61 1.65 (p  0.28) 12.77 12.99 (p  0.99)
Preoperative radiotherapy 4.35 3.31 (p  0.67) 2.13 0 (p  0.19)
Postoperative radiotherapy 45.22 31.40 (p  0.02)a 65.96 35.06 (p  0.001)a
Preoperative chemotherapy 5.22 11.57 (p  0.08) 6.38 10.39 (p  0.44)
Postoperative chemotherapy 3.48 22.31 (p  0.001)a 12.77 44.16 (p  0.001)a
Numbers in brackets are p values.
aUnderline statistical significance.
SQCLC, squamous cell lung cancer; ADC, adenocarcinoma.
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Analysis of cancer history of patients revealed that
10.46% among the SQCLC patients and 5.75% among the
ADC patients presented a Head and Neck Cancer (HNC). In
SQCLC patients, it seemed 5.49 (9) years before the lung
cancer. In ADC patients, this interval was 5.3 (14) years. A
diagnosis of HNC was recorded in 0.95% of patients already
operated for SQCLC and in 0.62% of patients operated for
ADC. Tobacco-related bladder cancer preceded lung cancer
in 2.06% of SQCLC patients and in 1.85% ADC patient. It
followed the lung primary in 0.79% of SQCLC patients and
in one patient with ADC.
Twenty-one patients had a history of three different pri-
mary tumors. Interestingly, 31.25% of females with LCLC
(n  5) had a history of breast cancer. Thirteen patients
had a kidney cancer. Nine patients had a history of kidney
transplantation. Six others had previously a Hodgkin lym-
phoma.
About 7% of all patients had at least one first degree
relative with a cancer history, whereas 2% had 2 first degree
relatives with cancer: a lung, a head and neck or/and a
digestive tract cancer in most cases (50%) with colon cancer
being the most frequent. Varied cancers affected the other
half of such families with predominant prostate and breast
cancers in non-small cell lung cancer (NSCLC) patients.
Familial hematological malignancies concerned more ADC
patients, although breast and thyroid cancers were prepon-
derant between LCLC patients.
DISCUSSION
Early diagnosis constitutes the critical tool in the cur-
rent effort to diminish lung cancer mortality. The generalized
use of CT scan for earlier diagnosis and better staging plays
an important role.7,8
A weak but clear benefit in survival, adjusted for stage,
has been shown in this study for the post-TNM revision
period (1997–2007). More patients with stage IA were diag-
nosed during this period. Apart from an increased awareness
to follow populations at high risk, a more frequent use of CT
scan explains this observation. The absence of such a kind of
awareness explains the delayed diagnosis of ADC and even
LCLC in nonsmoking women before 1997. Furthermore,
additional treatments (chemo- and radiotherapy) demon-
strated opposite effects upon patients’ survival. Chemother-
apy became more frequent after 1997, whereas radiotherapy
decreased. Adjuvant and neo-adjuvant chemotherapy offered
a longer survival to our patients’ measurable benefit to our
patients after 1997.
Improved survival during recent years may also be linked
to better staging due to superior CT technique and equipment.
Positron emission tomography was introduced lately positron
emission tomography scan was introduced lately and none of
the patients of our cohort was benefited from it. The surgical
team remained unchanged but its surgical skills may be
improved over the years.
This study corroborates the validity of the established
cornerstones of lung cancer diagnosis and treatment: histol-
ogy and pTNM staging. Operated patients showed a discrete
postoperative survival pattern characterized by different
prognosis factors depending upon the histotype: age for
SQCLC patients, sex, and smoking habits for ADC patients.
Beyond these distinct patterns, stage remained the only com-
mon prognosis factor for survival in both groups.
In ADC patients with stage I disease, a tumor size 4
cm was an unfavourable prognosis factor. This may reflect
the correlation of the T with survival or a different pattern of
natural history for ADC. A cutoff size of 4 cm was proposed
to distinguish T2 from T3, based on correlation between T
size and survival in patients with NSCLC.9 In patients with a
pN0 NSCLC, a tumor size greater than 5 cm was associated
with a worse prognosis.10 In patients with stage I NSCLC, a
study reported 2 and 5 cm as the 2 cutoff sizes regarding the
prognosis.11 Similarly, tumor size was shown to be an inde-
pendent prognosis factor in patients operated for stage I
NSCLC, with 2 and 5 cm being the thresholds of prognosis
modification.12 The addition of stage IIA in the WHO staging
system has been proven of limited value because it concerns
very few patients. Alternatively, measuring the tumor size
might be more helpful for the postoperative management of
the patients.
Gender seemed as a favorable predictor in ADC pa-
tients. Women had better prognosis and lesser postoperative
mortality. Female sex seemed also as a favorable prognosis
factor in many studies.13,14 A lower postoperative mortality
FIGURE 1. Kaplan-Meier stage-adjusted survival curves de-
scribing the survival rates among patients with squamous
cell lung cancer (SQCLC).
FIGURE 2. The stage-adjusted survival rates among pa-
tients with adenocarcinoma (ADC).
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was likewise reported for French women.15 We found this
advantage for women only in ADC, due perhaps to the few
women among the SQCLC patients.
Being less than 50 years old is correlated with a longer
stage-adjusted survival only in patients with SQCLC. This
confirms earlier reports.13,16,17 Relative survival of all patients
was found to be decreased with age at diagnosis, regardless of
stage or demographics.18
Postoperative mortality remained stable throughout the
study period, though a decrease in pneumonectomies is found
during the recent years. Being older than 75 was a negative
predictor for postoperative mortality in patients with SQCLC.
This is consistent with the presence of a greater comorbidity
and has already been reported.19,20 Nevertheless, it may be
also linked to more pneumonectomies performed in elderly
SQCLC comparing with ADC patients (14 versus 4).
Long survivors presented a different profile depending
on histology. Stage was the only common predictive factor
for long survivors. Among SQCLC patients, younger subjects
with earlier stages tended to live longer. Long survivors with
ADC were fewer than those with SQCLC and were mostly
women and never smokers. Tumor and host-related biologic
factors have been hypothesized for this advantage of female
patients with ADC.21 Patients with a history of HNC seem
particularly at risk for presenting a second primary lung
cancer.22 Therefore, a close follow-up has to be proposed for
patients with heavy smoking and previous HNC. It should
exceed 5 years after diagnosis. For patients with a HNC
history, the lung tumor is most often a SQCLC (2/1, com-
paring with ADC). This may be due to the “field effect” of
tobacco smoking.23
Our study presents a number of limitations and one of
them is that not all the relevant characteristics have been
recorded. This is mainly due to the initial design of our
database (1988). At that time, only the presented character-
istics were appeared as clinically relevant.
Biobanks are able to demonstrate that a collegial man-
agement and extended survey benefit lung cancer patients.
They are doing more than distributing patients’ samples for
research. Biobanks are hospital structures able to help the
evaluation of the effects of new medical practices for lung
cancer management.
Overall and stage-adjusted survival of operated lung
cancer patients has been improved in the last decade due
mainly to earlier diagnosis. The generalized use of CT scan,
chemotherapy, and a collegial management improved pa-
tients’ survival.
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